17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape
Key Takeaways
- Average THC concentration in illicit cannabis flower has risen from under 4 percent in the 1990s to roughly 15 to 20 percent, and concentrates commonly exceed 60 to 90 percent.
- Inhaled THC produces effects within minutes, while oral ingestion is delayed 30 to 120 minutes and peaks at 2 to 4 hours, which drives the dose-stacking pattern behind most edible overdoses.
- First-pass hepatic metabolism converts oral THC to 11-hydroxy-THC, a more potent psychoactive metabolite that explains why edibles feel stronger than equivalent inhaled doses.
- Delta-8 THC and other semi-synthetic hemp-derived cannabinoids are sold in unregulated markets with inconsistent purity and residual reaction byproducts.
- Only three cannabinoid medications have FDA approval: dronabinol, nabilone and cannabidiol (Epidiolex); no whole-plant cannabis product is FDA-approved.
17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape
Quick Answer: Delta-9-THC is a partial agonist at presynaptic CB1 receptors. Average flower potency has risen from under 4% THC in the early 1990s to roughly 15 to 20% today, with concentrates (wax, shatter, distillate, live resin) commonly 60 to 90%. Inhaled THC acts within minutes; oral THC is delayed 30 to 120 minutes, peaks at 2 to 4 hours, and is converted by first-pass metabolism to the more potent 11-hydroxy-THC. Only dronabinol, nabilone and cannabidiol (Epidiolex) are FDA-approved cannabinoid medications.
1. Why Potency Matters Clinically
Cannabis use disorder, acute psychosis and cannabinoid hyperemesis syndrome all track with total THC exposure, not with "whether the patient uses cannabis." A patient dabbing concentrate three times daily and a patient smoking one low-potency joint on weekends share a diagnosis label and almost nothing else.
| Product | Typical THC | Notes |
|---|---|---|
| Illicit flower, early 1990s | Under 4% | The evidence base most clinicians were trained on |
| Contemporary flower | About 15 to 20% | Dispensary and illicit markets converge here |
| Hashish | 20 to 40% | Compressed resin |
| Concentrates (wax, shatter, budder, live resin) | 60 to 80% | Dabbing delivers a very large bolus |
| Distillate and vape cartridges | 70 to 90%+ | Highest available concentration |
| Edibles | Dose-labeled in mg | A standardized serving is commonly 5 to 10 mg THC; packages often contain 100 mg |
| Tinctures | Variable | Sublingual absorption partially bypasses first pass |
Teaching anchor: ask for grams per day and product type, not "how much do you smoke?" A gram of 80% concentrate contains roughly 800 mg of THC — the equivalent of 80 to 160 standardized edible servings.
2. Route Determines Everything About Onset
| Route | Onset | Peak | Duration | Key clinical issue |
|---|---|---|---|---|
| Inhaled (smoked or vaporized) | Seconds to minutes | 15 to 30 minutes | 2 to 4 hours | Self-titration is possible; bronchial irritation; highest reinforcement |
| Oral (edible) | 30 to 120 minutes | 2 to 4 hours | 6 to 8+ hours | Dose stacking — the patient eats more because "nothing is happening" — is the leading cause of acute cannabis toxicity presentations |
| Sublingual / tincture | 15 to 45 minutes | 1.5 to 3 hours | 4 to 8 hours | Partial first-pass bypass |
| Rectal / topical | Variable / minimal systemic | — | — | Topicals do not produce intoxication |
The 11-hydroxy-THC point
Oral THC undergoes hepatic first-pass conversion to 11-hydroxy-THC, which crosses the blood-brain barrier readily and is more psychoactive than delta-9-THC itself. This is why an edible dose that matches an inhaled dose on paper produces a stronger, longer and more dysphoric experience — and why edible-related emergency visits skew toward panic, paranoia and, in older adults, cardiac symptoms.
3. Pharmacokinetics That Drive Drug Testing
- THC is highly lipophilic and redistributes to adipose tissue.
- Terminal elimination half-life in chronic heavy users is roughly 5 to 13 days.
- Urine screening detects the inactive metabolite THC-COOH, which can remain positive for 30 or more days after cessation in daily users, and often 3 to 7 days in occasional users.
- A positive urine cannabinoid screen therefore does not establish current impairment. This matters enormously in custody, employment, transplant and pain-agreement contexts, and is a point the APRN is frequently asked to explain.
4. The Unregulated Cannabinoid Market
| Product | What it is | Risk |
|---|---|---|
| Delta-8 THC | Semi-synthetic, usually converted from hemp-derived CBD using acid catalysis | Residual reagents and unidentified byproducts; inconsistent labeling; intoxicating despite being marketed as "legal hemp" |
| Delta-10, THC-O-acetate, HHC | Further semi-synthetic derivatives | Even less characterized; THC-O-acetate raised specific inhalation-toxicity concerns |
| High-dose CBD products | Marketed for anxiety, pain, sleep | Real drug interactions: CBD inhibits CYP2C19 and CYP3A4 and can raise clobazam, warfarin and tacrolimus levels; hepatotoxicity at high doses |
| Synthetic cannabinoid receptor agonists (K2, Spice) | Full CB1 agonists, structurally unrelated to THC | Seizures, acute kidney injury, severe agitation, death; not detected on routine cannabinoid immunoassay |
Key distinction for the exam: THC is a partial CB1 agonist, which is why fatal overdose from cannabis itself is not described. Synthetic cannabinoid receptor agonists are full agonists with far greater efficacy, which is why they cause seizures, renal failure and deaths.
5. FDA-Approved Cannabinoid Medications
| Drug | Composition | Indication | Schedule |
|---|---|---|---|
| Dronabinol (Marinol, Syndros) | Synthetic delta-9-THC | Chemotherapy-induced nausea and vomiting; AIDS-related anorexia | Schedule III (capsules); Syndros solution Schedule II |
| Nabilone (Cesamet) | Synthetic THC analogue | Chemotherapy-induced nausea and vomiting | Schedule II |
| Cannabidiol (Epidiolex) | Plant-derived purified CBD | Lennox-Gastaut, Dravet syndrome, tuberous sclerosis complex | Descheduled |
No whole-plant or dispensary cannabis product is FDA-approved for any indication. When a patient says "my cannabis is medical," the accurate framing is that it is state-authorized, not FDA-approved, and has not undergone the potency, purity and efficacy review that applies to prescription drugs.
A patient ate a cannabis edible, felt nothing after 45 minutes, and ate three more servings. Four hours later he presents with panic, tachycardia and paranoid ideation. Which pharmacologic feature best explains this presentation?
A patient in a chronic pain program has a positive urine cannabinoid screen and reports he last used cannabis 12 days ago. The pain clinic wants to discharge him for "using today." What should the APRN explain?
Which statement correctly distinguishes delta-9-THC from synthetic cannabinoid receptor agonists such as K2 or Spice?